TOP TEN perturbations for 38844_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38844_at
Selected probe(set): 202590_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38844_at (202590_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
dysferlinopathy study 2 (LGMD2B; severe) / normal vastus lateralis tissue
Relative Expression (log2-ratio):-2.148921Number of Samples:2 / 6
Experimental | dysferlinopathy study 2 (LGMD2B; severe) |
Biopsies of vastus lateralis muscle from male patients with limb-girdle muscular dystrophy 2B (LGMD2B) and severe fibrotic replacement. All subjects showed evidence of a dystrophic process (degeneration/regeneration of muscle fibers) and dysferlin mutation. | |
Control | normal vastus lateralis tissue |
Biopsies of vastus lateralis muscle from young adult volunteers. Samples were taken as normal controls from baseline samples of exercise experiments. |
male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):2.1078405Number of Samples:2 / 8
Experimental | male infertility study 1 (juvenile; Ad-) |
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells. | |
Control | normal testicular lobules tissue (mJS10) |
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):-2.0134869Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):1.8706789Number of Samples:5 / 8
Experimental | male infertility study 1 (juvenile; Ad+) |
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells. | |
Control | normal testicular lobules tissue (mJS10) |
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-1.8688736Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):1.7585287Number of Samples:15 / 2
Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
Control | uterine/pelvic pathology study 2 (late se MCP) |
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):-1.7205877Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)
Relative Expression (log2-ratio):1.6998949Number of Samples:6 / 10
Experimental | diphenylcyclopropenone study 1 (late) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
Control | diphenylcyclopropenone study 1 (early) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):1.6988935Number of Samples:9 / 3
Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
Control | normal skeletal muscle tisuue (fetal) |
Commercially purchased normal fetal skeletal muscle tissue samples. |
diphenylcyclopropenone study 1 (early) / placebo treated skin tissue
Relative Expression (log2-ratio):-1.6823406Number of Samples:10 / 11
Experimental | diphenylcyclopropenone study 1 (early) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- | |
Control | placebo treated skin tissue |
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days. |